anti oxidant omega 3

ApprovedSmall molecule

WWoman's Health University Hospital, Egypt

anti oxidant omega 3 is one of 7 small molecule programs targeting Oligohydramnios. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OligohydramniosActive, not recruiting

OligohydramniosApproved

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Oligohydramnios

#DrugCompanyPhaseTrials

Coumadin

AAbbott

Approved

1 2

Viagra

VViatris Specialty LLC

Phase 2

1 3

Imdur

OOmnivium

Phase 2

1 4

anti oxidant omega 3

WWoman's Health University Hospital, Egypt

Approved

1 5

L-Arginine

Mario Negri Institute for Pharmacological Research

Phase 2

1 6

Prostaglandins E2

TTel-Aviv Sourasky Medical Center

Phase 3

1 7

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oligohydramnios1 trial

Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial

Completed·WWoman's Health University Hospital, Egypt·Phase 4·NCT01990690·202 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for anti oxidant omega 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — anti oxidant omega 3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for anti oxidant omega 3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Woman's Health University Hospital, Egypt company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: WWoman's Health University Hospital, Egypt

anti oxidant omega 3

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oligohydramnios1 trial

References

Drug Info

Quick Facts

Related News